References
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008. PMID 18981485 · PMC2757071 · doi:10.7326/0003-4819-149-9-200811040-00003↩
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev 2018. PMID 28400207 · PMC5632578 · doi:10.1016/j.sxmr.2017.02.004↩
- Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991. PMID 1939523 · doi:10.1210/jcem-73-5-1081↩
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. PMID 18031173 · doi:10.2165/00063030-199912020-00007↩
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997. PMID 9141536 · doi:10.1210/jcem.82.5.3943↩
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683 · doi:10.1210/jc.2005-1536↩
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006. PMID 17018654 · doi:10.1210/jc.2006-1702↩
- Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. PMID 10496658 · doi:10.1023/a:1018955126402↩
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822 · doi:10.1530/eje.0.1390552↩
- Bowers CY, Reynolds GA, Durham D, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990. PMID 2108187 · doi:10.1210/jcem-70-4-975↩
- U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin for injection) prescribing information, BLA022505 (openFDA drug label, effective 20260729). openFDA Drug Label API 2026. Source↩
- Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019. PMID 31301983 · doi:10.1016/S2213-8587(19)30084-1↩
- Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med 2008. PMID 18347346 · doi:10.7326/0003-4819-148-10-200805200-00215↩




